Resolution on the results of the Council of Experts on the topic “In search of effective methods for the diagnosis and treatment of malignant neoplasms caused by NTRK gene rearrangements, malignant neoplasms in children and adolescents caused by NTRK gene fusions”

1. Vaishnavi A., Le A.T., Doebele R.C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34. doi: 10.1158/2159-8290.CD-14-0765.

2. Сулейманова А.М., Сагоян Г.Б., Киргизов К.И. Новые подходы в терапии солидных опухолей у детей и подростков с использованием таргетного препарата энтректиниб. Российский журнал детской гематологии и онкологии 2019;6(4):62–8. doi: 10.21682/2311-1267-2019-6-4-62-68.

3. Stransky N., Cerami E., Schalm S., Kim J.L., Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. doi: 10.1038/ncomms5846.

4. Chetty R. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes. J Clin Pathol. 2019;72(3):187–90. doi: 10.1136/jclinpath-2018-205672.

5. Hsiao S.J., Zehir A., Sireci A.N., Aisner D.L. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefi t from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn. 2019;21(4):553–71. doi: 10.1016/j.jmoldx.2019.03.008.

6. Solomon J.P., Hechtman J.F. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res. 2019;79(13):3163–8. doi: 10.1158/0008-5472.CAN-19-0372.

7. Gatalica Z., Xiu J., Swensen J., Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147–53. doi: 10.1038/s41379-018-0118-3.

8. Conde E., Hernandez S., Sanchez E., Regojo R.M., Camacho C., Alonso M., Martinez R., Fernando Lopez-Rios. Pan-TRK Immunohistochemistry An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Arch Pathol Lab Med. 2021;145(8):1031–40. doi: 10.5858/arpa.2020-0400-RA.

9. Drilon A., Laetsch T.W., Kummar S., DuBois S.G., Lassen U.N., Demetri G.D., Nathenson M., Doebele R.C., Farago A.F., Pappo A.S., Turpin B., Dowlati A., Brose M.S., Mascarenhas L., Federman N., Berlin J., El-Deiry W.S., Baik C., Deeken J., Boni V., Nagasubramanian R., Taylor M., Rudzinski E.R., Meric-Bernstam F., Sohal D.P.S., Ma P.C., Raez L.E., Hechtman J.F., Benayed R., Ladanyi M., Tuch B.B., Ebata K., Cruickshank S., Ku N.C., Cox M.C., Hawkins D.S., Hong D.S., Hyman D.M. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Eng J Med. 2018;378(8):731–9. doi: 10.1056/NEJMoa1714448.

10. Mascarenhas L. et al. Poster presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstr. 10030.